Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956486 · ClinicalTrials.gov registry record · Phase 3
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
A Phase 3 study, sponsored by Eisai Co..
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,212
- Enrollment target
NCT02956486: Clinical Trial Phase 3 study, sponsored by Eisai Co..
NCT02956486 is a Phase 3 study that was terminated before completion, run by Eisai Co.. The registered enrollment target is 2,212 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (187% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02956486, a Phase 3 study, was terminated before completion, sponsored by Eisai Co..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,212 participants
- Enrollment target
Study Summary
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Primary Outcome
The clinical dementia rating (CDR) scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobb
Interventions
- DRUG Placebo
- DRUG Elenbecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,212 participants |
| Start Date | 2016-10-20 |
| Est. Completion | 2020-01-15 |
| Phase | Phase 3 |
Why NCT02956486 stopped before completion
NCT02956486 is an interventional study that assigns participants to a tested intervention. Its 2,212 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (187% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02956486 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02956486 about?
NCT02956486 is a clinical study titled "A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease". The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, plac...
What is the current status of trial NCT02956486?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,212 participants. The study started on 2016-10-20. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT02956486?
The interventions under investigation include: Placebo (DRUG), Elenbecestat (DRUG).
Who is sponsoring clinical trial NCT02956486?
This trial is sponsored by Eisai Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02956486's enrollment target sits among peer trials
2,212 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI